SCHEMBL3762984

SCHEMBL3762984

CC(C)Oc1cccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
ACHE P22303 1/20 0.43
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
GFER P55789 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAP4K1 Q92918 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
MAPK1 P28482 4/20 0.41
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773249 0.91 KDM2B (0.51) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3773820 0.89 ACHE (0.47) ALDH1A1MAPTKDM4ECYP2C19LMNA
SCHEMBL3766886 0.87 NPSR1 (0.47) ALDH1A1MAPTKDM4ECYP2C9CYP2C19
SCHEMBL3767958 0.86 SLC6A7 (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3768207 0.86 MAPT (0.49) ALDH1A1MAPTKDM4ECYP2C9CYP2C19
SCHEMBL3762866 0.84 ALDH1A1 (0.64) ALDH1A1MAPTKDM4ECYP2C9CYP2C19
SCHEMBL3765964 0.84 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL3767567 0.84 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ECYP2C9CYP2C19
SCHEMBL3777299 0.84 MAPK1 (0.55) ALDH1A1MAPTKDM4ELMNAHTT
SCHEMBL3771074 0.84 KMT2A (0.59) ALDH1A1MAPTLMNAMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885MAPT 1475/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.